Williams Cancer Institute

PDAC TREATMENT: NANOFLUIDICS AND CD40 MAB

PDAC TREATMENT: NANOFLUIDICS AND CD40 MAB


The pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer of the exocrine pancreas, often diagnosed in advanced stages with a low survival rate.

Immunotherapy, particularly with CD40 agonist monoclonal antibodies (mAb), shows promise in overcoming the immunosuppressive nature of the PDAC tumor microenvironment, transitioning from a cold to hot tumor.

However, challenges arise due to limitations in systemic administration and potential adverse effects.

In a study conducted by Liu et al. in 2023, it was demonstrated that sustained intratumoral delivery of low doses of CD40 mAb via the nanofluidic drug-eluting seed (NDES) could modulate the tumor immune microenvironment (TIME), reducing the tumor burden in murine models.

The NDES achieves tumor reduction with a fourfold lower dosage than systemic treatment, avoiding treatment-related adverse events.

Additionally, abscopal responses are observed, where intratumoral treatment inhibits the growth of untreated tumors at a distance.

The NDES emerges as a viable approach to overcome the immunological barrier in PDAC in a minimally invasive and effective manner, with the primary goal of transforming treatment.

Reference: Hsuan-Chen Liu, Daniel Davila Gonzalez, Dixita Ishani Viswanath, Robin Shae Vander Pol, Shani Zakiya Saunders, Nicola Di Trani, Yitian Xu, Junjun Zheng, Shu-Hsia Chen, Corrine Ying Xuan Chua, Alessandro Grattoni, 19 January 2023, Sustained Intratumoral Administration of Agonist CD40 Antibody Overcomes Immunosuppressive Tumor Microenvironment in Pancreatic Cancer, https://onlinelibrary.wiley.com/doi/full/10.1002/advs.202206873?fbclid=IwAR0C4jQBtrE8ZKTfOtKeBeDjf3kNOUZUD3Q8ke9MhRhJKl_HHSnO-5osiFs_aem_AfC8c5_w_GNKwjPCtgM1U62JcYXgoZtIkjyzMMXHLSFF7nRLqI6ZAkQrPjtBVwE5Wqs

Related Posts

Blog 23 de mayo de 2024
Blog 21 de mayo de 2024
Blog 20 de mayo de 2024
1 2 3 111